Pay in 4 interest-free payments of $7.02 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
A clear, evidence-based overview for patients and clinicians 1
Dont let chronic fatigue, metabolic imbalances, or persistent mood disorders hold you back
These people have always returned my emails & calls
Phase 2 trial data (Jastreboff et al., NEJM 2023) demonstrated average weight reductions of approximately 1724% over 48 weeks notably higher than currently approved GLP-1 receptor agonists such as semaglutide, though direct comparisons are limited by differences in trial populations and designs
Frequently Asked Questions Got Questions on Dietary Supplements
US$ 20.57
US$ 22.24
US$ 25.98
US$ 26.40
